Two weeks post-tumor injection, mice were randomized into 4 groups (8 mice per group): untreated, treated with anti-PD-1, treated with IGF1R inhibitor (AEW), and treated with a combination of anti-PD-1 and the IGF1R inhibitor (anti-PD-1/IGF1R). This evidence concerns the gene PDCD1 and neoplasm.